In the Matter of GlaxoSmithKline, PLC (Augmentin)
States alleged that GlaxoSmithKline fraudulently obtained patent protection for Augmentin and then delayed generic entry through sham patent litigation. Through this conduct, GlaxoSmithKline unlawfully maintained its monopoly over Augmentin. A $3.5 million multistate settlement for state proprietary claims was entered into by the participating states and GlaxoSmithKline.
In Re Relafen Antitrust Litigation
States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.
Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
North Carolina ex rel. Cooper v. McClure et al., No. 03 CVS 005617 (Wake County Super. Ct. 2003)
State alleged a group of environmental consulting firms conspired to rig bids and inflate prices that the state pays to clean sites contaminated by leaking petroleum tanks.
State ex rel. Cooper v. McLeod Oil Co., No 05 CVS 13975 (N.C. Super Wake Co. July 30, 2007)
State alleged gasoline supplier and its affiliate conspired with other gasoline retailers to force gas station to raise its prices significantly. Parties settled for $25,000 civil penalties,
North Carolina ex rel. Cooper v. Byrd et al., Nos. 05CVS8038 through 3047 (Wake County Super. Ct. 2005)
State alleged parties conspired to fix prices and rig bids for public auctions of real estate
located in Raleigh, Cary, Chapel Hill, Durham, Angier, Apex, Hillsborough communities. The conspiracy involved properties that were up for routine auction through county Clerks of Superior Court due to foreclosure.
U.S. et al. v. EchoStar Communications, Corp., et al. No. 1:02CV02138 (D.D.C.)
Federal and State action to enjoin merger of two direct broadcast satellite (DBS) companies. The merging parties abandoned their merger agreement
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint
Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.
New York v. Microsoft Corp., 97 F. Supp. 2d 59 (D.D.C. 2000)
U.S. Department of Justice and the Plaintiff States alleged that the Defendant, Microsoft Corporation violated State and Federal law by maintaining a monopoly in the market for Intel-compatible personal computer operating systems and by illegally tying its Windows operating system to its Internet Explorer browser.
Texas v. Zeneca, 1997 U.S. Dist. LEXIS 13153 (N.D. Tex. 1997)
States sought an injunction and monetary damages from Zeneca, Inc. (Zeneca), alleging that the company conspired with distributors of its crop protection chemicals to maintain the resale price of the chemicals.
